Opus Genetics, Inc. (NASDAQ:IRD) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Opus Genetics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are broadly positive: Opus Genetics has a “Moderate Buy” consensus among 19 analysts, with 16 buy and one strong-buy rating. The average 12-month price target is $13.29.
  • Quarterly results missed expectations: The company reported a loss of $0.46 per share versus the $0.15 loss analysts expected, while revenue of $1.14 million fell short of the $1.55 million consensus.
  • Insiders sold 673,805 shares worth about $3.21 million over the past 90 days; the reported CFO and CEO sales were to cover tax withholding on vested equity awards.
  • Five stocks to consider instead of Opus Genetics.

Shares of Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nineteen analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $13.29.

A number of research analysts have issued reports on IRD shares. Royal Bank Of Canada upped their target price on shares of Opus Genetics from $9.00 to $11.00 and gave the company an "outperform" rating in a report on Wednesday, November 11th. TD Cowen assumed coverage on Opus Genetics in a research report on Wednesday, July 29th. They set a "buy" rating for the company. Chardan Capital reiterated a "buy" rating and issued a $16.00 price target on shares of Opus Genetics in a research report on Thursday, October 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Opus Genetics in a report on Thursday, October 15th. Finally, Wall Street Zen downgraded shares of Opus Genetics from a "hold" rating to a "sell" rating in a research note on Saturday, November 7th.

Read Our Latest Analysis on Opus Genetics

Insider Activity at Opus Genetics

In other Opus Genetics news, CFO Robert E. Gagnon sold 14,000 shares of the company's stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $3.55, for a total value of $49,700.00. Following the completion of the transaction, the chief financial officer directly owned 542,375 shares in the company, valued at $1,925,431.25. This represents a 2.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 28,258 shares of the company's stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.90, for a total transaction of $110,206.20. Following the completion of the transaction, the chief executive officer owned 2,010,636 shares of the company's stock, valued at approximately $7,841,480.40. This trade represents a 1.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 673,805 shares of company stock valued at $3,213,582. 11.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Opus Genetics

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Opus Genetics in the second quarter valued at $12,809,000. Nantahala Capital Management LLC acquired a new stake in shares of Opus Genetics in the 2nd quarter valued at about $12,582,185. Trails Edge Capital Partners LP bought a new position in shares of Opus Genetics during the 2nd quarter worth approximately $11,276,434. ADAR1 Capital Management LLC increased its holdings in Opus Genetics by 4,522.5% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company's stock valued at $8,413,000 after buying an additional 1,809,004 shares during the period. Finally, Marshall Wace LLP boosted its position in Opus Genetics by 62.5% during the 3rd quarter. Marshall Wace LLP now owns 3,161,606 shares of the company's stock worth $15,302,000 after buying an additional 1,215,997 shares during the period. 14.97% of the stock is owned by institutional investors and hedge funds.

Opus Genetics Stock Performance

Shares of NASDAQ IRD opened at $4.08 on Friday. The company has a 50 day simple moving average of $4.39 and a two-hundred day simple moving average of $4.27. The company has a current ratio of 9.65, a quick ratio of 9.65 and a debt-to-equity ratio of 0.90. The stock has a market cap of $394.33 million, a price-to-earnings ratio of -2.62 and a beta of 0.80. Opus Genetics has a 12 month low of $1.86 and a 12 month high of $7.07.

Opus Genetics (NASDAQ:IRD - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.31). The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.55 million. As a group, analysts predict that Opus Genetics will post -0.56 earnings per share for the current year.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company's therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.

Read More

Analyst Recommendations for Opus Genetics (NASDAQ:IRD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Opus Genetics Right Now?

Before you consider Opus Genetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opus Genetics wasn't on the list.

While Opus Genetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines